Transcatheter Mitral Valve Replacement: A New Arrow in the Bow

Original Title: Transcatheter Mitral Valve Replacement in Native Mitral Valve Disease With Severe Mitral Annular Calcification: Results From the First Multicenter Global Registry Reference: J Am Coll Cardiol Intv. 2016;9(13):1361-1371. doi:10.1016/j.jcin.2016.04.022 Gentileza del Dr. Agustín Vecchia. The risk underlying the surgical approach to mitral valve replacement in patients with severe mitral annular calcification is high. A<a href="https://solaci.org/en/2016/07/15/transcatheter-mitral-valve-replacement-a-new-arrow-in-the-bow/" title="Read more" >...</a>

Valve-in-Valve: High or Low Implantation for Better Outcomes?

Original Title: Transcatheter Replacement of Failed Bioprosthetic Valve. Large Multicenter Assessment of the Effect of Implantation Depth on Hemodynamics after Aortic Valve-in Valve. Reference: Matheus Simonato, et al. Circ. Cardiovasc. Interv 2016;9:e003651   Courtesy of Dr. Carlos Fava.   At present, most patients undergoing surgical valve replacement receive a bioprosthetic valve, which lasts from 10 to<a href="https://solaci.org/en/2016/07/12/valve-in-valve-high-or-low-implantation-for-better-outcomes/" title="Read more" >...</a>

Percutaneous mitral valve replacement: First steps

Original Title: Percutaneous Transvenous Transseptal Transcatheter Valve Implantation in Failed Bioprosthetic Mitral Valves, Ring Annuloplasty, and Severe Mitral Annular Calcification. Reference: Eleid MF et al. JACC Cardiovasc Interv. 2016 Jun 13;9(11):1161-74.   Courtesy of Dr. Agustín Vecchia.   Transfemoral percutaneous transvenous mitral valve implantation is a promising technique and, despite the fact that no devices<a href="https://solaci.org/en/2016/06/16/percutaneous-mitral-valve-replacement-first-steps/" title="Read more" >...</a>

TAVI at 10 Years: First Study to Assess TAVI Long Term Durability

Original Title: First look at long-term durability of transcatheter heart valves: Assessment of valve function up to 10 years after implantation. Presenter: Danny Dvir.   Transcatheter aortic valve implantation (TAVI) is being used in increasingly younger patients at low surgical risk, which is why longer survival is expected. The durability of transcatheter aortic prostheses has<a href="https://solaci.org/en/2016/05/19/tavi-at-10-years-first-study-to-assess-tavi-long-term-durability/" title="Read more" >...</a>

The SAPIEN 3 Valve Resulted Superior to Surgery in an Observational Study

The last generation of the balloon expandable valve resulted superior to surgery in intermediate riskpatients, in a registry analyzis. Patients treated with the SAPIEN 3 valve showed lower rates of death, stroke and paravalvular leak at one year than patients undergoing surgery. This third generation improves the SAPIEN XT with a skirt designed to prevent<a href="https://solaci.org/en/2016/04/08/the-sapien-3-valve-resulted-superior-to-surgery-in-an-observational-study/" title="Read more" >...</a>

Impact of the Right Atrial Pressure on FFR measurement

Original Title: Impact of the Right Atrial Pressure on Fractional Flow Reserve Measurements Comparison of Fractional flow Reserve and Myocardial Fractional flow Reserve in 1600 Coronary Stenosis. Reference: Toth G, et al. JACC Cardiovasc Interv. 2016 Feb 12. Epub ahead of print. Courtesy of Dr. Guillermo Migliaro. Fractional Flow Reserve (FFR) is the gold standard for the<a href="https://solaci.org/en/2016/02/29/impact-of-the-right-atrial-pressure-on-ffr-measurement/" title="Read more" >...</a>

TAVR é um procedimento tão seguro e eficaz quanto a substituição cirúrgica num seguimento de dois anos em pacientes de menor risco.

Fundamentos e  Objetivos: A substituição da válvula aórtica via transcateter (TAVR) é uma opção em determinados pacientes cirúrgicos de alto risco com estenose da válvula aórtica grave. Desconhecemos se a TAVR pode ser introduzida com segurança para os pacientes de baixo risco. O estudo NOTION (Nordic Aortic Valve Intervention Trial) é um ensaio clínico randomizado<a href="https://solaci.org/en/2015/06/24/tavr-e-um-procedimento-tao-seguro-e-eficaz-quanto-a-substituicao-cirurgica-num-seguimento-de-dois-anos-em-pacientes-de-menor-risco-2/" title="Read more" >...</a>

JUPITER: transapical TAVI device

We evaluated 88 consecutive patients (at this phase) with severe aortic stenosis who received the second-generation device for transapical access. Survival at thirty days was 85.1% with a cardiovascular death rate of 4.8%. No strokes were observed during this period. Average gradient reduction was highly significant, (40.4 to 8.1 mmHg, p <0.001), as well as<a href="https://solaci.org/en/2015/06/24/jupiter-transapical-tavi-device/" title="Read more" >...</a>

DISCOVER: new low profile valve with little post-implant regurgitation

The objective of the study was to assess events after 30 days with the DirectFLOW Medical Valve device in patients with severe aortic stenosis and high surgical risk. The device is designed to reduce post-implant aortic regurgitation; it has a low profile and high navigability and requires no post-dilatation or rapid pacing. The study included<a href="https://solaci.org/en/2015/06/24/discover-new-low-profile-valve-with-little-post-implant-regurgitation/" title="Read more" >...</a>

Educational Journal N° 97

SINDROME CORONARIO AGUDO • Infarto Agudo de Miocardio: Nuevo Paradigma en el tratamiento de STEMI – Dr. Luis Guzmán • Nuevas estrategias de reperfusión miocárdica en el Infarto Agudo de Miocardio con Elevación del Segmento ST – Dr. José Armando Mangione ANGIOPLASTIA TRANSLUMINAL CORONARIA EN SITUACIONES ESPECIALES • ¿Cuál es la mejor estrategia en las bifurcaciones? – Dr.<a href="https://solaci.org/en/2015/05/19/educational-journal-n-97/" title="Read more" >...</a>